These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 38617510)
1. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification. Chen Z; Du D; Li J; Zhang W; Shao J Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510 [TBL] [Abstract][Full Text] [Related]
2. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma. Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062 [TBL] [Abstract][Full Text] [Related]
3. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma. Jiang H; Chen H; Wang Y; Qian Y J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710 [TBL] [Abstract][Full Text] [Related]
4. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma. Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201 [TBL] [Abstract][Full Text] [Related]
5. A novel cuproptosis-related prognostic gene signature and validation of differential expression in hepatocellular carcinoma. Li Y; Zeng X Front Pharmacol; 2022; 13():1081952. PubMed ID: 36703728 [No Abstract] [Full Text] [Related]
6. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma. Wang S; Bai H; Fei S; Miao B Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914 [TBL] [Abstract][Full Text] [Related]
7. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma. Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L Front Genet; 2023; 14():1056000. PubMed ID: 36845390 [No Abstract] [Full Text] [Related]
8. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. Yan C; Niu Y; Ma L; Tian L; Ma J J Transl Med; 2022 Oct; 20(1):452. PubMed ID: 36195876 [TBL] [Abstract][Full Text] [Related]
9. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma. Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X Front Oncol; 2023; 13():1182434. PubMed ID: 37346073 [TBL] [Abstract][Full Text] [Related]
10. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma. Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL Front Oncol; 2023; 13():1153353. PubMed ID: 37056336 [TBL] [Abstract][Full Text] [Related]
11. Ferroptosis and cuproptosis prognostic signature for prediction of prognosis, immunotherapy and drug sensitivity in hepatocellular carcinoma: development and validation based on TCGA and ICGC databases. Ma Q; Hui Y; Huang BR; Yang BF; Li JX; Fan TT; Gao XC; Ma DY; Chen WF; Pei ZX Transl Cancer Res; 2023 Jan; 12(1):46-64. PubMed ID: 36760376 [TBL] [Abstract][Full Text] [Related]
12. Identification and Validation of Ubiquitin-Specific Proteases as a Novel Prognostic Signature for Hepatocellular Carcinoma. Ni W; Bian S; Zhu M; Song Q; Zhang J; Xiao M; Zheng W Front Oncol; 2021; 11():629327. PubMed ID: 33718205 [TBL] [Abstract][Full Text] [Related]
13. A novel cuproptosis-related prognostic signature and potential value in HCC immunotherapy. Wang XX; Wu LH; Ji H; Liu QQ; Deng SZ; Dou QY; Ai L; Pan W; Zhang HM Front Mol Biosci; 2022; 9():1001788. PubMed ID: 36250008 [No Abstract] [Full Text] [Related]
14. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer. Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X Front Immunol; 2022; 13():1056932. PubMed ID: 36479114 [TBL] [Abstract][Full Text] [Related]
15. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma. Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831 [TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-related long non-coding RNAs model that effectively predicts prognosis in hepatocellular carcinoma. Huang EM; Ma N; Ma T; Zhou JY; Yang WS; Liu CX; Hou ZH; Chen S; Zong Z; Zeng B; Li YR; Zhou TC World J Gastrointest Oncol; 2022 Oct; 14(10):1981-2003. PubMed ID: 36310708 [TBL] [Abstract][Full Text] [Related]
17. A novel cuproptosis-related gene signature for overall survival prediction in patients with hepatocellular carcinoma. Yang F; Jiang S; Liu Y; Zhang T; Zhu C; Zhang L; Sang X; Lu X; Wei J; Deng K; Zheng Y; Xu Y Heliyon; 2022 Nov; 8(11):e11768. PubMed ID: 36468143 [TBL] [Abstract][Full Text] [Related]
18. Identification of cuproptosis and ferroptosis-related subgroups and development of a signature for predicting prognosis and tumor microenvironment landscape in hepatocellular carcinoma. Yang BF; Ma Q; Hui Y; Gao XC; Ma DY; Li JX; Pei ZX; Huang BR Transl Cancer Res; 2023 Dec; 12(12):3327-3345. PubMed ID: 38192999 [TBL] [Abstract][Full Text] [Related]
19. DLAT as a Cuproptosis Promoter and a Molecular Target of Elesclomol in Hepatocellular Carcinoma. Gao F; Yuan Y; Ding Y; Li PY; Chang Y; He XX Curr Med Sci; 2023 Jun; 43(3):526-538. PubMed ID: 37286711 [TBL] [Abstract][Full Text] [Related]
20. A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma. Zhang Q; Ma L; Zhou H; Zhou Y; Liu S; Li Q Front Oncol; 2022; 12():1040736. PubMed ID: 36324575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]